Adam Koppel has bought stock on 4 days since Jan 2018

Adam M. Koppel, MD, PhD is a Partner at Bain Capital Life Sciences, where he initially joined Bain Capital Public Equity in 2003 as a leader in the healthcare sector until 2014, rejoined in 2016 after serving as Executive Vice President of Corporate Development and Chief Strategy Officer at Biogen (2014-2016), and now focuses on life sciences investments.( Prior to Bain, he was an Associate Principal at McKinsey & Company in New Jersey, advising healthcare companies.( As a Director holding 10% ownership, he recently traded shares in Kailera Therapeutics, Inc. (KLRA), and currently serves on the boards of Areteia Therapeutics, Cardurion Pharmaceuticals, Kailera Therapeutics, and Beeline Medicines, with prior board roles at Aptinyx, Cerevel Therapeutics, Dicerna Pharmaceuticals, Foghorn Therapeutics, PTC Therapeutics, Solid Biosciences, Trevena, Inc., and ViaCyte.(

Koppel earned an MD and PhD in neuroscience from the Perelman School of Medicine at the University of Pennsylvania, an MBA from the Wharton School (Palmer Scholar), and graduated magna cum laude from Harvard University with AB and AM degrees in history and science.( He is Chairman of the Board of Trustees of the Boston Museum of Science, serves on boards including Newton-Wellesley Hospital, CJP Boston, and The William Penn Charter School, and holds positions on the Society for Neuroscience Investment Committee, Harvard Medical School Discovery Council, and Mass General Brigham Innovation Growth Board.(

Written by Perplexity from public sources.